Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
B of A Securities Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $39
B of A Securities analyst Tazeen Ahmad initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy rating and announces Price Target of $39.
Cantor Fitzgerald Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $41
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight rating and announces Price Target of $41.
Wells Fargo Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $38
Wells Fargo analyst Mohit Bansal initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight rating and announces Price Target of $38.
Goldman Sachs Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $28
Goldman Sachs analyst Madhu Kumar maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target from $24 to $28.
Benzinga’s Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades
See all analyst ratings upgrades.
Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why
Mizuho updated the price target for Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) from $27 to $32 keeping the Neutral rating. The updated model…
Mizuho Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $32
Mizuho analyst Graig Suvannavejh maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target from $27 to $32.
Morgan Stanley Maintains Overweight on Cerevel Therapeutics Hldg, Raises Price Target to $50
Morgan Stanley analyst Matthew Harrison maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight and raises the price target from $39 to $50.
Cerevel Therapeutics Shares Are Falling: Here’s Why
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 7.1% to $32.00 during Tuesday's trading session after the company priced its underwritten common stock offering of 7.25 million shares at $35 per share.
What Else?